… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … review of the Company’s clinical-stage programs and RNAediting technology platforms. A webcast replay of the …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … scientific advisory board. Dr. Yu’s research focuses on RNAediting and his expertise will help to develop the Company’s …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … Annual Conference A presentation titled “Therapeutic RNAediting by Axiomer ® editing oligonucleotides” by Janne …
… two companies will work together to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis targets … collaboration are not disclosed. ProQR is developing its RNA platform technology in areas of ophthalmology, cystic … look forward to collaborating with ProQR and its exciting RNAediting technologies.” About ProQR ProQR Therapeutics is …
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … scientific advisory board Dr. Yu’s research focuses on RNAediting and his expertise will help to develop the …